Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin Added to Insulin in Type 2 Diabetes
NCT00757588Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2008
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Saxagliptin + insulin with Placebo + insulin (2 arms). Primary endpoint: Adjusted Mean Change From Baseline in A1C Levels at 24 weeks. Started Nov 2008; status: completed.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00757588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00757588.